NewAmsterdam Pharma Company N.V. cleared a significant regulatory milestone when the European Commission approved two cholesterol-reduction medications on September 21. Ubeslo contains 10 mg of obicetrapib, while Evlarco combines 10 mg of obicetrapib with 10 mg of ezetimibe. Both treatments represent the first global approvals for these formulations and are intended for adults with primary high cholesterol or mixed lipid disorders, with treatment eligibility determined by existing therapy and statin tolerance.
The medicines address a substantial unmet need among patients requiring additional low-density lipoprotein cholesterol reduction beyond maximum tolerated therapy. Clinical trial data demonstrated statistically significant LDL-C reductions of up to 40 percent with obicetrapib and approximately 50 percent with the ezetimibe combination across the Phase 3 program. The combination approach may offer convenience benefits through simplified dosing compared to separate pill regimens.
Menarini holds exclusive European commercialization rights under an agreement that entitles NewAmsterdam Pharma to tiered royalties ranging from low double-digit percentages to the mid-20% range on net sales within the licensed territory. The partnership also includes potential clinical, regulatory, and commercial milestone payments totaling up to €833 million, contingent on specified achievements. As of June 30, 2026, NewAmsterdam Pharma reported $678.3 million in cash, cash equivalents, and marketable securities.
Commercialization success depends on multiple factors beyond regulatory approval. Reimbursement decisions, prescribing restrictions, and negotiated pricing will determine patient access and resulting net sales. The company continues development spending, with second-quarter research and development expenses at $41.7 million, and the organization remains unprofitable with a net loss of $64.1 million in that period.
A separate cardiovascular-outcomes trial called PREVAIL, which enrolled more than 9,500 patients, will test whether obicetrapib reduces major cardiovascular events. An interim analysis was planned for the fourth quarter of 2026, with results expected in the first quarter of 2027. Cholesterol reduction alone does not establish that these products prevent heart attacks or strokes, making the PREVAIL outcomes data a potential determinant of longer-term commercial opportunity.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI